Login / Signup

An audit of the use of hydroxychloroquine in rheumatology clinics.

Claudia WorthImran H YusufBethany TurnerHanae GourierEmma E BrooksDaniel O MortSrilakshmi SharmaSusan M DownesRaashid A Luqmani
Published in: Rheumatology advances in practice (2018)
HCQ therapy is being used for >5 years in 29% of patients with rheumatic diseases, with higher than recommended doses in ∼10% of patients. We recommend more rigorous scrutiny of the use of HCQ to reduce the risk of retinopathy.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • primary care
  • prognostic factors
  • stem cells
  • rheumatoid arthritis
  • mesenchymal stem cells
  • disease activity